Saturday, January 03, 2026 6:16:24 PM
It's awfully hard to say LP lied when she says little to nothing with definitive targets. I believe she could even defend her remarks at the Annual Meeting a year and a half ago about the company being very different now, it is, who back then would have ever thought we'd be aligned with Roswell, Pittsburg, own Advent, etc. Sure we didn't get the approval we thought would occur and the market gave no value to these other changes, but who can deny how positive the changes are. Eventually these changes will be reflected in the share price right along with the approval of the vaccine in the UK, and perhaps with others piggybacking in the not that distant future.
While I feel certain that LP, LG, and others felt certain of approval some time ago, only LG ever opined on how quickly I believe. I still believe that the UK regulators have wanted to see EDEN progress, in the back of their minds, so that as demand builds they believe the supply will become available. None of this will never be known unless someone knowledgeable decides to write a book, etc. and if it happens it will be biased by the view of the authors. As for investors, we'll be spoon fed what management believes we should be told, and very little more.
Gary
While I feel certain that LP, LG, and others felt certain of approval some time ago, only LG ever opined on how quickly I believe. I still believe that the UK regulators have wanted to see EDEN progress, in the back of their minds, so that as demand builds they believe the supply will become available. None of this will never be known unless someone knowledgeable decides to write a book, etc. and if it happens it will be biased by the view of the authors. As for investors, we'll be spoon fed what management believes we should be told, and very little more.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
